A quantitative assessment of alkaptonuria-Reference-Cited by-同舟云学术

A quantitative assessment of alkaptonuria

Published:2011-07-09 Issue:6 Volume:34 Page:1153-1162
ISSN:0141-8955
Container-title:Journal of Inherited Metabolic Disease
language:en
Short-container-title:J Inherit Metab Dis

Author:

Cox Trevor F.,Ranganath Lakshminarayan

Publisher

Wiley

Subject

Genetics (clinical),Genetics

Link

http://www.springerlink.com/index/pdf/10.1007/s10545-011-9367-8

Reference15 articles.

1. Beck M (2006) The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease. Acta Pædiatrica Suppl 451:43–46

2. Bland JM, Altman DG (1997) Statistical Notes: Chronbach’s alpha. BMJ 314:572

3. Committee for Medicinal Products for Human Use (CHMP) (2006) Guidelines on clinical trials in small populations (CHMP/EWP/83561/2005). European Medicines Agency, London

4. Cox TF, Cox MAA (2001) Multidimensional Scaling. Chapman & Hall, Boca Raton

5. D’Agostino RB (2009) The delayed-start study design. N Engl J Med 361(13):1304–1306

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alkaptonuria;Nature Reviews Disease Primers;2024-03-07

2. Doenças de depósito: ocronose, Fabry e Gaucher;Revista Paulista de Reumatologia;2023-06-30

3. Identification of Potential Inhibitors for the Treatment of Alkaptonuria Using an Integrated In Silico Computational Strategy;Molecules;2023-03-14

4. Clinical development innovation in rare diseases: overcoming barriers to successful delivery of a randomised clinical trial in alkaptonuria—a mini-review;Orphanet Journal of Rare Diseases;2023-01-04

5. Alkaptonuria – Past, present and future;Advances in Clinical Chemistry;2023